Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP)

Miguel Á. Sanz(Instituto de Investigación Sanitaria La Fe), John J. Isitt(Amgen (United States)), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Susan D. Mathias(Health Outcomes Solutions (United States)), Xuena Wang(Tianjin University of Traditional Chinese Medicine)
Value in Health
January 1, 2011
10.1016/j.jval.2010.10.017
Cited by 30

Related Papers

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
|Blood|2009|3.4k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
|Blood|2008|957